The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Motor Functioning In Young People With Attention Deficit Hyperactivity Disorder – Combined Type: A Three-dimensional Motion Analysis Study.
Funder
National Health and Medical Research Council
Funding Amount
$477,065.00
Summary
Attention deficit hyperactivity disorder –combined type (ADHD-CT) is a complex neuropsychiatric disorder with a progressively devastating impact on psychosocial development. The first objective of this study is to use 3D-motion analysis to ‘probe’ the underlying brain dysfunction which characterises ADHD-CT. The second objective of this study is to improve our understanding of the link between movement problems, and (a) injury proneness, and (b) social-communicative problems, in children with AD ....Attention deficit hyperactivity disorder –combined type (ADHD-CT) is a complex neuropsychiatric disorder with a progressively devastating impact on psychosocial development. The first objective of this study is to use 3D-motion analysis to ‘probe’ the underlying brain dysfunction which characterises ADHD-CT. The second objective of this study is to improve our understanding of the link between movement problems, and (a) injury proneness, and (b) social-communicative problems, in children with ADHD-CT.Read moreRead less
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.